Now playing: LA Existential
GOOD MORNING. Happy Thursday from Beverly Hills where the Milken Institute Global Conference wrapped up last night. Drop us a line at dgardiner@politico.com and mmason@politico.com or on X — @DustinGardiner and @melmason. For the latest on other Golden State political news, don't miss this afternoon's edition of California Playbook PM.
LA-LA LAND'S CLOSE-UP — To paraphrase the late Tip O'Neill, all multi-day global issues conferences are local.
Okay, maybe that's a stretch. But many of the discussions on the final day of the Milken Institute confab were distinctly rooted in its host city — to the palpable relief of prominent Angelenos in attendance.
'I'm just so enthused by the amount of people that are in this room, and especially people that aren't from Los Angeles,' said Cinny Kennard, executive director of the Annenberg Foundation, who was clearly pleased that conference-goers cared enough about the city's wildfire recovery efforts to fill one of the venue's large ballrooms.
No one would call Los Angeles an overlooked backwater. But in this oversaturated news environment — and, let's face it, the national media's distinct East Coast bias — the city harbors a bit of an inferiority complex when it comes to the power broker crowd.
For the politicians repping the city, however, the attention at Milken required a delicate dance: Celebrating the successes they've had in the months after the fires without sounding tone-deaf about the considerable challenges that remain.
GLASS HALF FULL: Los Angeles Mayor Karen Bass told Playbook the No. 1 message she hoped to convey was that 'LA is doing okay. The entire city was not on fire. … We want the world to know that we are open for business.'
Bass and others appeared at an afternoon panel where an upbeat mood was established early — shoutout to whoever on the Milken team picked 'This Is How We Do It,' by LA's own Montell Jordan as the walk-on music.
Elected officials were quick to emphasize the speed of the recovery effort so far. One representative boast from LA County Supervisor Lindsey P. Horvath: 'We have led the fastest debris removal process in history, which has been a wild success.'
The Annenberg Foundation's Kennard touted the considerable philanthropic heft that's been amassed: $800 million raised so far. And while the state is still waiting to see if President Donald Trump will approve the supplemental spending for wildfire recovery Gov. Gavin Newsom has requested, Bass praised the White House for keeping the funding spigot open.
'The message is, 'Thank you.' Listen — credit where credit's due,' Bass said.
BUT BUT BUT: Panel moderator Elex Michaelson, a news anchor for the local Fox affiliate, did an admirable job pressing officials for more specifics, such as whether permits were being issued too slowly or whether — two and a half months after Bass sacked the city's fire chief — more heads would roll.
'There are a number of people that should be held accountable, and we're in the process of doing that,' Bass said, although she specified that potential firings would likely be months away, pending investigations into the city's fire response.
POLITICAL UNDERCURRENTS: One person who remains unimpressed is Rick Caruso, Bass' former rival for the mayorship who has been fiercely critical of the mayor's fire response.
The billionaire developer had been flitting around Milken for the past two days but was not in the audience for the discussion, which he initially had been slated to participate in. Caruso told Playbook he pulled out when he saw he'd be alongside Bass on stage, saying he feared the conversation would be a 'campaign stop.'
Caruso did see fit to publish an essay on the website of his rebuilding nonprofit, Steadfast LA, Wednesday morning in advance of the panel re-upping his blistering critiques — and yes, the timing was purposeful.
'I didn't want to look argumentative, but I did want to get my point of view out,' he said.
Caruso, who is widely seen as weighing another mayoral run or even a bid for governor, denied that his remarks should be read through a political lens, but rather from the vantage point of 'a guy that lost three homes, had a business completely shut down and expects better from its government.'
Bass, meanwhile, shrugged off Caruso's rebuke and the broader missives from her detractors.
'There's a lot of different motives,' she said. 'There are motives from different news channels who are very critical of any Democratic-run city. But my job is to not get mired in division and get mired in politics, but to stay focused on making sure the people in the Palisades get home as fast as possible.'
And speaking of politics, Playbook asked Horvath, whose name has been floated as a potential mayoral contender, if she had her eye on City Hall. She waved off that speculation — but only after noting that her supervisorial district just happens to overlap with nine LA city council districts.
'I've opened my committee to run for county supervisor. I'm focused on that, and, of course, the recovery and rebuild that people deserve,' she said.
HOLLYWOODLAND
LIGHTS, CAMERA, TAX CREDITS — Top Hollywood brass who spoke at Milken on Wednesday said they are not exactly clamoring for the national film tariffs Trump proposed in a somewhat inscrutable fashion earlier this week.
At 'The Future of Filmed Entertainment,' CNBC's Julia Boorstin asked an array of execs about Trump's trial balloon, and more broadly if the increase of filming abroad was a problem for the industry. While the studio bosses deftly avoided commenting directly on the president's proposal they all largely agreed declining production is a Golden State-specific woe, contrary to the president's claim that overseas film shoots amount to a threat to 'national security.'.
'While it's true a lot of production has left the United States, it's even worse for California,' said Ravi Ahuja, president and CEO of Sony Pictures.
The execs laid the blame on the state's film tax credit, which is substantially less than the perks offered by other states, such as Georgia, as well as other countries. Part of the issue is that California's available tax credits are capped, meaning that productions aren't guaranteed access to the incentives.
'Because it's capped, you can't plan,' said Casey Bloys, who runs HBO and Max Content. 'You have to get into a lottery, and you're not sure if your show is going to get the tax break or not. That uncertainty makes it very difficult, when you're looking at that versus Atlanta, versus Canada and others [where] you're guaranteed the incentive.'
Newsom and top Democrats have been working to double the tax break from roughly $330 million annually to $750 million. Negotiators have already hammered out a number of proposed changes to the existing program. But given the state's dire budget straits, an uncapped tax break is not in the cards, meaning it will be hard to match the largesse offered elsewhere.
'Certainly our credit, as proposed, will not be as competitive as a couple of the other jurisdictions. At the end of the day, we're going to lose production to Georgia, Vancouver and elsewhere,' acknowledged state Sen. Ben Allen, a Democrat from Los Angeles. 'We did know we had to make this work, we needed to increase the amount. It will bring a significant amount of work back, but do so in a way that makes everybody feel comfortable.'
Allen along with Assemblyman Rick Chavez Zbur and Newsom's chief economic adviser Dee Dee Myers delved deeper into the effort to keep Hollywood closer to home at a Wednesday afternoon panel that was, alas, off limits to reporters and off the record.
But Allen gave us a broad sense of the tone of the conversation, which he said centered on the urgency of getting an expanded California tax credit done — regardless of the curveball thrown by Trump about some federal-level help for the industry.
'The national conversation is intriguing and important. ... Especially everyone agrees on a national incentive [though there are] mixed reviews about tariffs, he said. 'But even if we do the most robust national program in the world, there's still going to be a challenge for California to keep work here vis-a-vis the Georgias and New Yorks and other parts of the country.'
TRADE
STARK WARNING — Citadel founder Ken Griffin used his conference-closing Q&A with institute Chair Michael Milken to reaffirm concerns that tariffs were 'contrary to the promise the president made to the American people' to ease inflation and improve cost of living concerns. While plenty of Wall Street heavyweights on the conference's main stage raised concerns about how trade policies could weaken markets, Griffin was one of the few to frame his criticism through the lens of the American consumer.
Griffin — a billionaire and powerful voice for the pre-Trump GOP orthodoxy — expanded on his concerns in an interview with our colleague Sam Sutton. 'Tariffs open the doors to crony capitalism. The government starts to pick winners and losers,' Griffin warned. Read more in today's edition of Morning Money.
ON THE GROUND
QUOTE OF THE DAY: 'Some of us have felt, in the last few years, there's no win being the president of a university.' — Michael Milken, as he posed a question to Dartmouth President Sian Beilock during the closing plenary session about … happiness.
PUPPY THERAPY — During the same panel, Franklin Templeton Investments CEO Jenny Johnson brought her bulldog on the stage. When Milken inquired about her 'financial adviser' on the stage, Johnson had a one-liner ready to go: 'The fact is, when you come home, your spouse or partner might be happy to see you. Your kids might be happy to see you. But your dog is ALWAYS happy to see you!' The camera panned to her canine companion as the audience laughed and cheered.
SPOTTED
AT THE BEVERLY HILTON: DAY FOUR — former California Gov. Gray Davis walking through the hallway
… California Community Foundation CEO Miguel Santana chatting with Snap CEO Evan Spiegel and Mayor Karen Bass in the lobby
… Golden Globes President Helen Hoehne, picking up her paper name plate outside the invite-only LA session
… Warner Bros. Discovery CEO David Zaslav milling in the hallway
… Sony Pictures chief Ravi Ahuja having a one-on-one meeting with Bass
… Assemblymember Rick Chavez Zbur ordering a to-go lunch in the Hilton lobby bar
… Allen chatting in the lobby bar with Jonathan Nolan, the screenwriter and producer who made Westworld and Memento
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Politico
a day ago
- Politico
Tariff lobbying shows little success
With Daniel Lippman, Daniel Desrochers and Ari Hawkins FIRST IN PI: Countries across the globe have dropped tens of millions this year on lobbyists with ties to President Donald Trump as they rushed to stave off tariffs that could cripple their economies. In most cases, the spending has gotten them nowhere, Caitlin, Daniel Desrochers and Ari Hawkins report for Pros. — At least 30 nations hired new lobbyists with connections to Trump since the election. They include major trading partners like South Korea and Japan as well as smaller countries like Bosnia and Ecuador. But employing those lobbyists appeared to bear little relation to whether the countries were able to avoid the most punishing tariffs. — 'I think the current leadership in Washington seems to be disrupting the traditional way of doing things,' said Mukesh Aghi, the CEO of the US-India Strategic Partnership Forum. 'I think the whole old model of trying to influence does not seem to work.' — The new model is punishing India. After bringing longtime Trump adviser Jason Miller on board in April, the nation has nonetheless been walloped by Trump over the past two weeks. Tariffs for India are now set to rise to 50 percent, after the country failed to secure a trade agreement and Trump decided to jack up tariffs in response to its purchase of Russian oil. — Canada and Mexico's handling of the tariff discussions exemplify two different approaches to lobbying Trump. Five of Canada's 10 provinces brought on new lobbying or public relations help in the last year. Mexico, by contrast, has just a single lobbying firm, Pillsbury Winthrop Shaw Pittman, on retainer, to provide legal services on trade issues. — Yet despite Mexico playing a more direct role in the flow of fentanyl, it was the neighbor to the north that ultimately faced steeper tariffs. Canada now has a 35 percent tariff on its goods, while Mexico has stayed at 25 percent. Mexico appeared to benefit from what one Mexican official described as personal ties between Trump and Sheinbaum. — Pros can read the full story here. Others can find it on POLITICO's homepage tomorrow morning. Happy Friday and welcome to PI. This is Daniel B. at the controls again, wishing everyone a good weekend. The weather in Washington is set to be beautiful, so send Caitlin and me tips on all your rooftop events. You can email us at dbarnes@ and coprysko@ or ping us on Signal at danielbarnes.13 and caitlinoprysko.17. And be sure to follow us both on X at @dnlbrns and @caitlinoprysko. FIRST IN PI II — FARA FRIDAY: The Embassy of Sudan has hired Vogel Group to lobby Congress and the Trump administration on humanitarian and foreign relations policy issues, according to documents filed with the Justice Department last week. — The contract, which was signed earlier this summer and runs through the end of the year, will net Vogel Group $40,000 per month from the African nation that has had an ongoing civil war since 2023. Alex Vogel, Matt Keelen, Ali Khimji and Andrew Nehring will handle the account with Tony Carroll consulting. — Trump, who has long sought a Nobel Peace Prize, expressed a desire to facilitate an end to the fighting in Sudan during a July meeting with other African leaders, during which he touted an earlier U.S.-backed peace deal between the Democratic Republic of Congo and Rwanda. — Peace may not be the only topic of conversation between administration officials and Vogel Group. People from Sudan have been fully banned from entering the U.S. since Trump signed his latest travel ban in June. And various sanctions against the Sudanese government remain in place. — Vogel did not immediately respond to a request for comment. — Additional filings show that Sudan previously hired Ballard Partners on a six-month contract in October 2024. That contract, which earned Ballard $300,000 total for work similar to the Vogel contract, lapsed in April and was not extended. FIRST IN PI III — ANOTHER ANTI-EXPORT CONTROLS OP-ED FAILS TO DISCLOSE NVIDIA TIES: A tech CEO who wrote an op-ed this week slamming export controls on artificial intelligence chips didn't disclose that his company has deep ties to chipmaker Nvidia, Daniel L. reports. — Aaron Ginn, the CEO of Hydra Host, wrote in The Wall Street Journal that 'it has become painfully obvious that Washington's strategy of restricting chip exports isn't working' and that 'America needs to start shipping AI to the world before it's too late, including to China.' Nvidia has been at the center of a debate in Washington about whether it and other American chipmakers should be allowed to sell advanced semiconductor chips to China. — But his op-ed didn't mention that his AI infrastructure company is an official Nvidia cloud partner and rents Nvidia chips. Three weeks ago, Ginn posted on LinkedIn a photo with Nvidia CEO Jensen Huang, saying that he had 'an incredible private dinner' with him and that 'so much rides on one simple idea: exporting American AI and becoming the world's default strategic AI platform, from chips to models.' — Ginn and Hydra Host didn't respond to requests for comment. A Journal spokesperson and a Nvidia spokesperson both declined to comment. — PI wrote last week that former Trump national security adviser Robert O'Brien had written an op-ed criticizing aggressive export controls on chips but also didn't disclose that his geopolitical advisory firm quietly works for Nvidia. PRIVATE EQUITY MOVES: Penta Group, which formed from the 2022 merger of Hamilton Place Strategies, Ballast Research, Flag Media Analytics, Alva, Gotham Research Group and Decode M, has been acquired by Los Angeles-based investment firm Shamrock Capital. — It's the latest example of private equity investment in K Street, and a strong bet on the stakeholder communications firm that has grown from a single Washington shop to a global firm with offices in Europe and Asia. The firm was previously sold to Falfurrias Capital Partners in 2021. The terms of this new deal were not disclosed. Jobs report — Melanie Lampton recently joined Babst Calland in the firm's Pipeline and HazMat Safety practice group. Lampton arrives from the Office of General Counsel at the Department of Energy, where she worked on legislative issues and department rulemaking. — Austin Stukins joins Politexts as executive vice president of partnerships and operations. He was previously vice president of business development for Push Digital Group. — American Economic Liberties Project has added Olivia Webb Kosloff as a senior fellow. She was most recently editorial lead for the Bio + Health fund at Andreessen Horowitz. — Grady Thomson is now an account executive at BerlinRosen. He previously served as communications coordinator for the Treasury Department. — The Institute for Global Affairs at the Eurasia Group has added Rudina Hajdari and Elizabeth Shackelford to lead two new pilot programs: the International Democracy Fellowship and the Summer Geopolitics Academy. Hajdari is a former member of the Albanian Parliament and Shackelford is a former U.S. diplomat most recently at the Dickey Center at Dartmouth. New Joint Fundraisers Adam Schwarze Victory Fund (Schwarze For Senate, No Fail Mission PAC, Sheepdog PAC) Rounds Victory Committee (Sen. Mike Rounds, The Peter Norbeck Leadership PAC) Walker Victory Fund (Winning Alabama For Liberty And Keep Electing Republicans, Committee To Elect Rodney Walker) New PACs Alabama Conservative Coalition (Hybrid PAC) Fellowship PAC (Super PAC) The New Day Coalition (Super PAC) American Dawoodi Bohras PAC (PAC) Just A Chill Company (PAC) 4THE56 (Super PAC) Time To Lead PAC (Super PAC) Protecting Animals With Solutions PAC (Super PAC) Winning Alabama For Liberty And Keep Electing Republicans (Leadership PAC: Rodney Walker) New Lobbying REGISTRATIONS Akin Gump Strauss Hauer & Feld: Dci Group Az LLC (Fka Dci Group Az, L.L.C.) American Defense International, Inc.: Red Cell Partners, LLC Bbt Strategies LLC: Waterfront Global Cornerstone Government Affairs, Inc.: Diplomatic Perspective Efb Advocacy, LLC: American Civil Liberties Union, Inc. Forward Global: Herman Law Franklin Creek Consulting: St. Croix Chippewa Indians Of Wisconsin Government Relations Group, LLC: Interport Logistics Government Relations Group, LLC: The Gift Box Heideman Nudelman & Kalik, Pc: Samvel Karapetyan Liberty Partners Group, LLC: Accentcare Mcguirewoods Consulting (A Subsidiary Of Mcguirewoods LLP): California Bioenergy LLC Port Side Strategies, LLC: Public Employees For Environmental Responsibility (Peer) Smartcontract Inc.: Smartcontract Inc. Thorn Run Partners: City Of Philadelphia - Department Of Aviation Velocity Government Relations: Assured Space Access, Inc. Vitello Consulting: Stonington Global On Behalf Of Tl Management New Lobbying Terminations Bondi Partners Advocacy Corp. (Fka Pacific Partners): Bubs Australia Gotham Government Relations: Nyc Organization Of Public Service Retirees, Inc. Ice Miller LLP: Golden Beam Metals, LLC Red Maple Consulting, LLC: International Legal Finance Association Velocity Government Relations: Cognitive Space Velocity Government Relations: Ensemble Government Services, LLC


Politico
a day ago
- Politico
Kidney patients see opportunity in RFK Jr.'s upheaval
WASHINGTON WATCH Advocates for patients with kidney disease are calling on Health Secretary Robert F. Kennedy Jr. to go ahead and fire the members of the U.S. Preventive Services Task Force. The American Association of Kidney Patients, whose corporate members include drugmakers Amgen, Eli Lilly, and Sanofi, has warred with the panel for years over whether to expand screening for kidney disease. The association wants it to; the panel says it's studying the issue. 'The president and the secretary are committed to making America healthy again,' said Paul T. Conway, the kidney patients' chair of policy and global affairs. 'If that means throwing out things that have been there a while and shaking up the status quo, especially the medical status quo, no problem.' The panel's recommendations determine what insurers must cover without cost-sharing under a provision of the Affordable Care Act. In a letter to Kennedy, the kidney association's president, Edward V. Hickey III, says it's lost faith the current members have kidney patients' best interest in mind. 'The Task Force has not adequately considered all available evidence supporting kidney disease screening, including patient insight data, nor has it kept pace with new diagnostics and FDA-approved therapies that slow disease progression.' The association says that, at a minimum, screening of patients with a family history of kidney disease, diabetes or high blood pressure should be standard. Why it matters: Kennedy canceled a meeting of the expert panel in July and The Wall Street Journal later reported he planned to fire its members. After the meeting was canceled, scores of medical groups, including kidney doctors, wrote a letter to top lawmakers in protest. The medical groups said disrupting the task force would politicize it and undermine confidence in its recommendations. 'The loss of trustworthiness in the rigorous and nonpartisan work of the Task Force would devastate patients, hospital systems, and payers as misinformation creates barriers to accessing lifesaving and cost effective care,' they wrote. But the kidney patients' letter shows that some see an opportunity to advance their goals in Kennedy's willingness to reconsider the status quo. What's next? Kennedy hasn't detailed his plans since the Journal report on July 25. The task force typically would next meet in November. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. New research has uncovered clues about why some people who never smoked contract lung cancer. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. OPERATING ROOM xCures, which uses artificial intelligence to collect and organize patients' medical data, is launching a product that can help consumer health apps securely access patients' medical records. The launch will help advance individual access to medical records on the Trusted Exchange Framework and Common Agreement, an ecosystem for sending and receiving health data overseen by the Office of the National Coordinator for Health Information Technology, a division of the Department of Health and Human Services. 'The primary driver for this is getting me my data off of the network so that I can use it for my purposes,' xCures CEO Mika Newton told POLITICO. Health app developers can license xCures' product to allow patients to pull their medical data from multiple health systems into their apps. The new product can convert medical data into a usable format. Security concerns have previously prevented apps from being able to access patient records. Health systems and electronic health record companies want to ensure that patients requesting records are who they say they are. xCures works with CLEAR, an identity verification platform commonly found at airports, to confirm identities. To get access to their records, patients will have to submit a picture of a valid ID and complete a biometric face scan. The company is collaborating with a health system, which uses its own dedicated app through which patients can access their medical records, though Newton declined to name which health system is involved. TEFCA moves: xCures works with information broker Kno2, a qualified health information network, or QHIN, on TEFCA, to get patient data. QHINs can request data from others on TEFCA to help facilitate treatment, payment for services, health system operations, public health, government benefit determination, and individual access to health records. TEFCA is still in its early days. Even so, ONC reports that the ecosystem supports 41,000 unique connections to clinicians, hospitals, clinics, post-acute and long-term care facilities and public health departments. Last year, Epic, a large electronic health records company — and also a TEFCA QHIN — said it would let patients access their health records. While such technology can ease patient access to their medical data, it's unclear how secure their data will be outside of regulated health institutions. Federal health data rules don't protect consumer apps, raising questions about how secure patient data will be once it's transferred out of electronic health records. 'We ensure the security and proper storage of all data on our platform. Our data hosting supports essential processes like normalization, structuring, and source verification, which are key value additions we provide,' said Newton. He says his company requires app companies that license its individual access services to meet certain privacy and security standards. But once the data is transferred to the app, it is the responsibility of the app maker to protect it.


Politico
a day ago
- Politico
The shrinking number of advisory committee meetings
Driving the Day MAKARY'S ROUNDTABLES — FDA Commissioner Marty Makary seems to be shifting traditional advisory committee panels to review and provide recommendations on drug and medical device products in favor of communicating his regulatory priorities through podcasts or by roundtable discussion. 'FDA's new leadership team appears to see little value to the advisory committee forum as a venue to communicate important regulatory ideas or to provide public cover for potentially controversial regulatory actions,' TD Cowen's Rick Weissenstein wrote in a Thursday research note. While the year is not yet over, the FDA has held or scheduled only nine advisory committee meetings in 2025. That's a sharp drop from his predecessor's 38 advisory committee meetings in 2024, 45 meetings in 2023 and 21 meetings in 2022, according to the FDA's calendar. Dr. Reshma Ramachandran, co-director of the Yale Collaboration for Regulatory Rigor, Integrity and Transparency, raised concern that the roundtables have been moderated by political appointees. 'Unlike advisory committees where there would be a robust vetting process for members, there seems to be none besides making sure they generally align with ideological views,' Ramachandran said. 'It's also surprising to see limited participation from FDA career scientists whereas at an advisory committee meeting, they would be offering the agency's scientific view on a specific issue or question. Last month, Senate appropriators dinged Makary for holding roundtables on talc, infant formula and cell and gene therapies without accepting public comments. 'The Committee is concerned that the agency did not allow public participation or provide for public comments and panelists did not disclose potential conflicts of interest,' the lawmakers wrote in a nonbinding committee report. At the time, HHS called the characterization a 'misleading political attack.' But following its recent expert panel on menopause and hormone replacement therapy for women on July 17, the FDA opened a docket for the public to submit feedback, which is slated to remain open until Sept. 24. 'This request is part of the FDA's effort to understand various perspectives on these safety considerations and the use of hormone therapy for menopause-related conditions in clinical practice,' the agency said on the meeting's webpage. HHS did not respond to a request for comment. IT'S FRIDAY. WELCOME BACK TO PRESCRIPTION PULSE. August recess is here — and we're around for source coffees. Send tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). Eye on the FDA KEEP YOUR SHOES ON — In what sounds more like an airline's pre-check-in program, the FDA is launching its own PreCheck program — although this one fast-tracks new drug-manufacturing sites in the U.S. The new effort, announced Thursday by FDA Commissioner Marty Makary, aims to give manufacturers more frequent agency communication while they design pharmaceutical manufacturing facilities, construct the new buildings and stand up pre-production of medicines. The FDA also plans to conduct pre-application meetings to provide proactive feedback on drugmakers' chemistry, manufacturing and controls, a crucial part of drug applications. Looking ahead: The FDA is scheduled to hold a public meeting on Sept. 30 to discuss efforts to onshore manufacturing of drug and biological products and where to present a draft framework for the FDA PreCheck program. 'The FDA PreCheck initiative is one of many steps FDA is taking that can help reverse America's reliance on foreign drug manufacturing and ensure that Americans have a resilient, strong, and domestic drug supply,' Makary said in a statement. Fun fact: A former Center for Devices and Radiological Health official granted anonymity tells your host that the FDA previously wanted to use the PreCheck name for a different program — ultimately named the Software Precertification Pilot Program — but backed off because of the Transportation Security Administration's well-known program. In the courts MEDICARE PRICE TALK WIN — The drug industry took another loss in its series of legal challenges to the 2022 law allowing Medicare to negotiate drug prices on Thursday — this time with the 2nd U.S. Circuit Court of Appeals rejecting Boehringer Ingelheim's challenge and upholding a lower court ruling denying its claims. In its appeal, Boehringer — maker of the blockbuster diabetes drug Jardiance — argued that the program's construction violates its constitutional rights to free speech and due process and that CMS violated regulatory procedures law when it issued price agreements without taking public comment. 'The choice to participate in a voluntary government program does not become involuntary simply because the alternatives to participation appear to entail worse, even substantially worse, economic outcomes,' Circuit Judge William Nardini wrote in the decision. What's next: Boehringer could ask the 2nd Circuit for an en banc rehearing, in which all of the circuit's sitting judges would consider its arguments, or petition the Supreme Court to take the case. We're watching closely now that the industry has seen three losses — including for AstraZeneca and the U.S. Chamber of Commerce — at the appellate level. Boehringer did not respond to a request for comment. Also Thursday: A federal district court in Texas sided with the government in PhRMA's Inflation Reduction Act challenge, echoing other courts' determinations on the industry's constitutional claims. MEDICAL DEVICES PFAS IN DEVICES — The FDA's medical device center wants patients to know it currently does not believe there is a reason to restrict the use of per- and polyfluoroalkyl substances, or PFAS, in medical devices. That evaluation comes ahead of the anticipated release of the Trump administration's Make America Healthy Again report recommendations for action. 'The PFAS used in medical devices are not the same as those identified as being potentially harmful to people in other contexts,' the FDA said in a newly posted webpage. 'The PFAS materials used in medical devices (known as fluoropolymers) have a long history of use.' The agency said fluoropolymers are typically made of molecules 'too large to pass through cell membranes' and therefore are 'very unlikely to cause toxicity to patients.' 'We appreciate the FDA's confirmation that the PFAS used in medical technologies, such as lifesaving implanted devices, have a long track record of safety,' Scott Whitaker, CEO of medical device manufacturer trade group AdvaMed, said in a statement. AROUND THE AGENCIES FTC CHALLENGES VALVE DEAL — The Federal Trade Commission wants to stop Edwards Lifesciences' effort to acquire JenaValve Technology — a move the antitrust agency says could slash competition in a specialized heart valve market and potentially lead to higher prices for patients. The type of valve is called a transcatheter aortic valve replacement for aortic regurgitation, known as TAVR-AR. 'Edwards' attempt to buy the U.S. market for TAVR-AR devices would eliminate the head-to-head competition that has spurred innovation for lifesaving artificial heart valves,' Daniel Guarnera, director of the FTC's Bureau of Competition, said in a press release. The FTC Commission voted 3-0 to issue an administrative complaint and authorize staff to pursue a temporary restraining order and a preliminary injunction to block the transaction. Edwards said it plans to continue to pursue approval of the acquisition, which it argues will speed the availability and use of the treatment. 'Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation,' the company said in a statement. Pharma Moves Julie Tierney is joining health care consulting firm Leavitt Partners as a principal. She previously was the deputy director of the FDA Center for Biologics Evaluation and Research and was chief of staff to former FDA Commissioner Robert Califf and former Acting FDA Commissioner Janet Woodcock. Document Drawer The White House Office of Information and Regulatory Affairs is reviewing a rescission of the FDA's laboratory-developed tests final rule. The FDA has lifted its recommended pause of the use of the chikungunya vaccine Ixchiq in people ages 60 and older. WHAT WE'RE READING Efforts to encourage states to expand Medicaid coverage of anti-obesity drugs could be challenged by strained state budgets, Bloomberg Law's Celine Castronuovo reports. The Commonwealth Fund's Kristi Martin published an overview of how the 340B drug pricing program works and why it is attracting criticism.